Table 2.
Patient vital parameters, injury severity scores and the results of initial point-of-care assessments recorded at presentation to the study institution—survivors vs. non-survivors.
| Survivors (n = 39) | Non-survivors (n = 10) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Median | IQR | Median | IQR | P | Adjusted P | AUROC (95% CI) | Sens | Spec | |
| SAP (mmHg) | 141 | 117–158 | 129 | 93–168 | 0.459 | – | 0.587 (0.348–0.808) | 60.0% | 66.7% |
| MAP† (mmHg) | 103 | 91–118 | 96.5 | 81–101 | 0.225 | – | 0.627 (0.448–0.805) | 80.0% | 53.9% |
| Lactate (mmol/L) | 2.2 | 1.6–3.2 | 3.5 | 2.8–4.2 | 0.027 | – | 0.733 (0.595–0.872) | 100% | 56.4% |
| Shock index (AU) | 1.02 | 0.78–1.27 | 1.16 | 0.77–1.52 | 0.426 | 1.000 | 0.585 (0.363–0.806) | 50.0% | 76.9% |
| MGCS (AU) | 17 | 15–17 | 15 | 12–16 | 0.011 | 0.077 | 0.756 (0.577–0.936) | 90.0% | 56.4% |
| ATT (AU) | 4 | 4–6 | 6 | 5–7 | 0.012 | 0.084 | 0.750 (0.604–0.896) | 70.0% | 74.4% |
| SPI2 (AU) | 2.38 | 1.85–2.64 | 1.83 | 1.42–2.04 | 0.032 | 0.227 | 0.721 (0.542–0.899) | 80.0% | 69.2% |
| APPLE (AU) | 24 | 18–30 | 35 | 33–42 | <0.0001 | <0.0007 | 0.912 (0.878–0.995) | 90.0% | 84.6% |
| APPLEfast (AU) | 23 | 18–26 | 28 | 20–34 | 0.081 | 0.567 | 0.681 (0.486–0.876) | 50.0% | 84.6% |
| SOFA (AU) | 1 | 0–2 | 2 | 1–3 | 0.020 | 0.140 | 0.730 (0.570–0.889) | 100% | 30.8% |
P-values in bold type were significant at P < 0.05. For illness severity scores, a Bonferroni correction was applied to adjust for multiple comparisons (n = 7).
For the MAP data, n = 37 in the survivors group and 9 in the non-survivors group because for 3 dogs only a Doppler blood pressure was available. Those data are included in the SAP statistics. APPLE, acute patient physiologic and laboratory evaluation; ATT, acute trauma triage score; MAP, mean arterial pressure; SAP; systolic arterial pressure; SOFA, sequential organ failure assessment score; SPI2, survival prediction index-2.